Rosmarinic acid, a serious part of rosemary, is a polyphenolic compound with potential neuroprotective results. Asreducing the synaptic launch of glutamate is essential to reaching neuroprotectant’s pharmacotherapeutic results, the impact of rosmarinic acid on glutamate launch was investigated in rat cerebrocortical nerve terminals (synaptosomes). Rosmarinic acid depressed the 4-aminopyridine (4-AP)-induced glutamate launch in a concentration-dependent method. The removing of extracellular calcium and the blockade of vesicular transporters prevented the inhibition of glutamate launch by rosmarinic acid.
Rosmarinic acid decreased 4-AP-induced intrasynaptosomal Ca2+ elevation. The inhibition of N-, P/Q-type Ca2+ channels and the calcium/calmodulin-dependent kinase II (CaMKII) prevented rosmarinic acid from having results on glutamate launch. Rosmarinic acid additionally decreased the 4-AP-induced activation of CaMKII and the next phosphorylation of synapsin I, the primary presynaptic goal of CaMKII. As well as, immunocytochemistry confirmed the presence of GABAA receptors. GABAA receptor agonist and antagonist blocked the inhibitory impact of rosmarinic acid on 4-AP-evoked glutamate launch.
Docking knowledge additionally revealed that rosmarinic acid shaped a hydrogen bond with the amino acid residues of GABAA receptor. These outcomes instructed that rosmarinic acid prompts GABAA receptors in cerebrocortical synaptosomes to lower Ca2+ inflow and CaMKII/synapsin I pathway to inhibit the evoked glutamate launch.
Encapsulation of bioactive compounds from byproducts of two species of passionflowers: analysis of the physicochemical properties and managed launch in a gastrointestinal mannequin
This examine aimed to guage the discharge of energetic parts with antioxidant and antihypertensive capability from encapsulated extracts of the peel and seeds of Gulupa (Passiflora edulis f. edulis) and Cholupa (Passiflora maliformis) in an in vitro gastrointestinal digestion mannequin. Microencapsulated extracts have been ready with enzymatically modified rice starch because the encapsulating materials and ethanol extracts of seeds and peel of P. edulis f. edulis and P. maliformis as encapsulated materials. Microcapsule characterization was carried out by scanning electron microscopy with values of 4.54-5.13 μm and ξ potential values of -6.34 mV and -6.66 mV.
Dynamic gentle scattering (DLS) evaluation was performed with polydispersion values from 1.33 to 1.51, and dispersion stability evaluation was additionally performed. The overall phenol content material and antioxidant actions (ABTS, DPPH, and FRAP) and ACE inhibitory exercise (in vitro antihypertensive exercise) have been evaluated after every stage of digestion, with values higher than 80% of exercise earlier than gastrointestinal transit and with values higher than 55% exercise after the top of gastrointestinal transit. Gastrointestinal analysis of the encapsulated extracts was carried out with an ex vivo mannequin utilizing pig intestines and simulating the circumstances of digestion in three phases: the gastric (pH 2.Zero with 1.
Zero M HCl +0.5 g/L pepsin), enteric (pH 8.Zero with Krebs resolution +1.Zero mL/L bile) and last enteric (pH 7.5 Krebs resolution solely) phases. The microencapsulation of passionflower extracts confirmed good conduct in opposition to adjustments in pH and enzymatic actions all through digestion, thus selling a managed launch and focused supply of bioactive compounds, present process a paracellular mechanism by means of the intestinal barrier to protect the antioxidant exercise and ACE inhibitory that was proven by the extracts earlier than encapsulation of the fabric.
The impact of UV radiation on O-7 Actinomycete in producing bioactive compounds in numerous development circumstances
Actinomycetes have been recognized as an origin of many secondary metabolites, antibiotics and energetic parts that influence microbial development. Mediated mutations utilizing UV in follow for the breeding of organisms. The target of this examine is to analyses the influence of UV radiation on the (O-7) Actinomycete isolate. This was a potential analytical examine of a a number of of actinomycetes. The isolates have been screened for antimicrobial efficacy in opposition to a number of Gram-positive, Gram-negative micro organism, yeast, and fungi. Varied elements resembling UV, temperature, pH, gentle, agitation, fermentation durations and aeration have additionally been boosted for optimum antimicrobial manufacturing.
The isolate (O-7) Actinomycete has been acknowledged as a extremely bioactive producing organism. The isolate was uncovered to numerous wavelengths, instances underneath quite a few development circumstances. It was discovered that 4% focus of glucose as a carbon supply is considerably optimum for the manufacturing of antibiotic for (O-7) UV uncovered pressure, nonetheless, focus of 1% of lactose is considerably optimum for the manufacturing of antibiotic for (O-7) UV uncovered pressure. Yeast extract at a focus of 1% was discovered to be the very best supply of nitrogen for (O-7) UV uncovered, whereas pH 7.
Zero was discovered to be probably the most appropriate for a similar isolate. From the temperature optimization examine, it was noticed that (O-7) uncovered pressure confirmed good development and most antibiotic manufacturing at 28 °C. The soil-isolated organic compounds (O-7) have been efficient in opposition to sure sorts of micro organism and fungi, and the analysis additionally demonstrated that publicity to UV radiation enhanced the manufacturing of those compounds.Elucidating the switch of bioactive compounds between crops is important for understanding plant-plant interactions, growing pure pesticides and understanding their modes of motion. This text is protected by copyright. All rights reserved.
Translocation of metabolites between completely different plant species gives necessary hints in understanding the destiny of bioactive root exudates. Within the current examine, focused and untargeted mass spectrometry-based metabolomics was utilized to elucidate the switch of bioactive compounds between rye and a number of other crops and weed species. Our outcomes demonstrated that benzoxazinoids (BXs) synthesized by rye have been taken up by roots of neighbouring plant species and translocated into their shoots.
GPAT2 Recombinant Protein (Human) |
|||
| RP060951 | ABM | 100 ug | Ask for price |
Gpat2 ORF Vector (Rat) (pORF) |
|||
| ORF067727 | ABM | 1.0 ug DNA | EUR 607.2 |
GPAT2 ORF Vector (Human) (pORF) |
|||
| ORF020318 | ABM | 1.0 ug DNA | Ask for price |
Gpat2 ORF Vector (Mouse) (pORF) |
|||
| ORF046414 | ABM | 1.0 ug DNA | EUR 607.2 |
Gpat2 sgRNA CRISPR Lentivector set (Rat) |
|||
| K6080101 | ABM | 3 x 1.0 ug | EUR 406.8 |
Gpat2 sgRNA CRISPR Lentivector set (Mouse) |
|||
| K3673901 | ABM | 3 x 1.0 ug | EUR 406.8 |
GPAT2 sgRNA CRISPR Lentivector set (Human) |
|||
| K2772901 | ABM | 3 x 1.0 ug | EUR 406.8 |
GPAT2 3'UTR GFP Stable Cell Line |
|||
| TU059103 | ABM | 1.0 ml | EUR 2799.6 |
Gpat2 3'UTR GFP Stable Cell Line |
|||
| TU255284 | ABM | 1.0 ml | Ask for price |
Gpat2 3'UTR GFP Stable Cell Line |
|||
| TU158926 | ABM | 1.0 ml | Ask for price |
GPAT2 Protein Vector (Rat) (pPM-C-HA) |
|||
| PV270908 | ABM | 500 ng | EUR 1399.2 |
GPAT2 Protein Vector (Rat) (pPB-C-His) |
|||
| PV270906 | ABM | 500 ng | EUR 1399.2 |
GPAT2 Protein Vector (Rat) (pPB-N-His) |
|||
| PV270907 | ABM | 500 ng | EUR 1399.2 |
GPAT2 Protein Vector (Rat) (pPM-C-His) |
|||
| PV270909 | ABM | 500 ng | EUR 1399.2 |
GPAT2 Protein Vector (Human) (pPM-C-HA) |
|||
| PV081271 | ABM | 500 ng | Ask for price |
GPAT2 Protein Vector (Mouse) (pPM-C-HA) |
|||
| PV185656 | ABM | 500 ng | EUR 1278 |
GPAT2 Protein Vector (Human) (pPB-C-His) |
|||
| PV081269 | ABM | 500 ng | Ask for price |
GPAT2 Protein Vector (Human) (pPB-N-His) |
|||
| PV081270 | ABM | 500 ng | Ask for price |
GPAT2 Protein Vector (Human) (pPM-C-His) |
|||
| PV081272 | ABM | 500 ng | Ask for price |
GPAT2 Protein Vector (Mouse) (pPB-C-His) |
|||
| PV185654 | ABM | 500 ng | EUR 1278 |
GPAT2 Protein Vector (Mouse) (pPB-N-His) |
|||
| PV185655 | ABM | 500 ng | EUR 1278 |
GPAT2 Protein Vector (Mouse) (pPM-C-His) |
|||
| PV185657 | ABM | 500 ng | EUR 1278 |
GPAT2 3'UTR Luciferase Stable Cell Line |
|||
| TU009103 | ABM | 1.0 ml | EUR 2799.6 |
Gpat2 3'UTR Luciferase Stable Cell Line |
|||
| TU108926 | ABM | 1.0 ml | Ask for price |
Gpat2 3'UTR Luciferase Stable Cell Line |
|||
| TU205284 | ABM | 1.0 ml | Ask for price |
Gpat2 sgRNA CRISPR Lentivector (Rat) (Target 1) |
|||
| K6080102 | ABM | 1.0 ug DNA | EUR 184.8 |
Gpat2 sgRNA CRISPR Lentivector (Rat) (Target 2) |
|||
| K6080103 | ABM | 1.0 ug DNA | EUR 184.8 |
Gpat2 sgRNA CRISPR Lentivector (Rat) (Target 3) |
|||
| K6080104 | ABM | 1.0 ug DNA | EUR 184.8 |
Gpat2 sgRNA CRISPR Lentivector (Mouse) (Target 1) |
|||
| K3673902 | ABM | 1.0 ug DNA | EUR 184.8 |
Gpat2 sgRNA CRISPR Lentivector (Mouse) (Target 2) |
|||
| K3673903 | ABM | 1.0 ug DNA | EUR 184.8 |
Gpat2 sgRNA CRISPR Lentivector (Mouse) (Target 3) |
|||
| K3673904 | ABM | 1.0 ug DNA | EUR 184.8 |
GPAT2 sgRNA CRISPR Lentivector (Human) (Target 1) |
|||
| K2772902 | ABM | 1.0 ug DNA | EUR 184.8 |
GPAT2 sgRNA CRISPR Lentivector (Human) (Target 2) |
|||
| K2772903 | ABM | 1.0 ug DNA | EUR 184.8 |
GPAT2 sgRNA CRISPR Lentivector (Human) (Target 3) |
|||
| K2772904 | ABM | 1.0 ug DNA | EUR 184.8 |
GPAT1 Antibody |
|||
| 4613-002mg | ProSci | 0.02 mg | EUR 206.18 |
|
Description: GPAT1 Antibody: Glycerol-3-phosphate acyltransferase 1 (GPAT1), one of four known GPAT isoforms, is located on the mitochondrial outer membrane, allowing reciprocal regulation with carnitine palmitoyltransferase-1. It is thought to be critical for the development of hepatic steatosis; steatosis triggered by GPAT1 overexpression leads to hepatic and possibly peripheral insulin resistance. GPAT1 is transcriptionally upregulated by insulin and sterol regulatory element binding protein (SREBP-1) and downregulated by AMP-activated protein kinase. Mice deficient in GPAT1 exhibit decreased triacylglycerol (TAG) in cardiomyocytes even in high-fat diets, suggesting that GPAT1 contributes significantly to TAG accumulation in heart tissue during lipogenic or high fat diets. |
|||
GPAT1 Antibody |
|||
| 4613-01mg | ProSci | 0.1 mg | EUR 523.7 |
|
Description: GPAT1 Antibody: Glycerol-3-phosphate acyltransferase 1 (GPAT1), one of four known GPAT isoforms, is located on the mitochondrial outer membrane, allowing reciprocal regulation with carnitine palmitoyltransferase-1. It is thought to be critical for the development of hepatic steatosis; steatosis triggered by GPAT1 overexpression leads to hepatic and possibly peripheral insulin resistance. GPAT1 is transcriptionally upregulated by insulin and sterol regulatory element binding protein (SREBP-1) and downregulated by AMP-activated protein kinase. Mice deficient in GPAT1 exhibit decreased triacylglycerol (TAG) in cardiomyocytes even in high-fat diets, suggesting that GPAT1 contributes significantly to TAG accumulation in heart tissue during lipogenic or high fat diets. |
|||
GPAT1 Antibody |
|||
| 24687-100ul | SAB | 100ul | EUR 468 |
GPAT4 Antibody |
|||
| DF14685 | Affbiotech | 100ul | EUR 420 |
Gpat2 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Rat) |
|||
| K6080105 | ABM | 3 x 1.0 ug | EUR 451.2 |
GPAT-2 Antibody |
|||
| DF13583 | Affbiotech | 100ul | EUR 420 |
Gpat2 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Mouse) |
|||
| K3673905 | ABM | 3 x 1.0 ug | EUR 451.2 |
GPAT2 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human) |
|||
| K2772905 | ABM | 3 x 1.0 ug | EUR 451.2 |
Gpat2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 1) |
|||
| K6080106 | ABM | 1.0 ug DNA | EUR 200.4 |
Gpat2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 2) |
|||
| K6080107 | ABM | 1.0 ug DNA | EUR 200.4 |
Gpat2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Rat) (Target 3) |
|||
| K6080108 | ABM | 1.0 ug DNA | EUR 200.4 |
Polyclonal GPAT1 Antibody |
|||
| AMM05175G | Leading Biology | 0.1 mg | EUR 790.8 |
|
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human GPAT1 . This antibody is tested and proven to work in the following applications: |
|||
Gpat2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 1) |
|||
| K3673906 | ABM | 1.0 ug DNA | EUR 200.4 |
Gpat2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 2) |
|||
| K3673907 | ABM | 1.0 ug DNA | EUR 200.4 |
Gpat2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Mouse) (Target 3) |
|||
| K3673908 | ABM | 1.0 ug DNA | EUR 200.4 |
GPAT2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 1) |
|||
| K2772906 | ABM | 1.0 ug DNA | EUR 200.4 |
GPAT2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 2) |
|||
| K2772907 | ABM | 1.0 ug DNA | EUR 200.4 |
GPAT2 sgRNA CRISPR/Cas9 All-in-One Lentivector (Human) (Target 3) |
|||
| K2772908 | ABM | 1.0 ug DNA | EUR 200.4 |
Glycerol-3-Phosphate Acyltransferase 4 (GPAT4) Antibody |
|||
| 20-abx211974 | Abbexa |
|
|
Glycerol-3-Phosphate Acyltransferase 4 (GPAT4) Antibody |
|||
| 20-abx212042 | Abbexa |
|
|
Glycerol-3-Phosphate Acyltransferase 4 (GPAT4) Antibody |
|||
| 20-abx212043 | Abbexa |
|
|
Glycerol-3-Phosphate Acyltransferase 3 (GPAT3) Antibody |
|||
| 20-abx329242 | Abbexa |
|
|
GPATCH8 Antibody |
|||
| 45984-100ul | SAB | 100ul | EUR 302.4 |
GPATCH8 Antibody |
|||
| 45984-50ul | SAB | 50ul | EUR 224.4 |
GPATCH8 Antibody |
|||
| ABD9522 | Lifescience Market | 100 ug | EUR 525.6 |
GPATCH8 Antibody |
|||
| DF9522 | Affbiotech | 200ul | EUR 420 |
GPATCH2L Antibody |
|||
| DF16064 | Affbiotech | 100ul | EUR 420 |
anti- GPATCH2 antibody |
|||
| FNab03575 | FN Test | 100µg | EUR 658.5 |
|
Description: Antibody raised against GPATCH2 |
|||
anti- GPATCH4 antibody |
|||
| FNab03576 | FN Test | 100µg | EUR 702 |
|
Description: Antibody raised against GPATCH4 |
|||
GPATCH2 Polyclonal Antibody |
|||
| 29987-100ul | SAB | 100ul | EUR 302.4 |
GPATCH2 Polyclonal Antibody |
|||
| 29987-50ul | SAB | 50ul | EUR 224.4 |
GPATCH8 Conjugated Antibody |
|||
| C45984 | SAB | 100ul | EUR 476.4 |
GPATCH2 Polyclonal Conjugated Antibody |
|||
| C29987 | SAB | 100ul | EUR 476.4 |
SURP And G-Patch Domain Containing 2 (SUGP2) Antibody |
|||
| 20-abx324076 | Abbexa |
|
|
SURP And G-Patch Domain Containing 2 (SFRS14) Antibody |
|||
| 20-abx218818 | Abbexa |
|
|
SURP And G-Patch Domain Containing 2 (SFRS14) Antibody |
|||
| abx237788-100ug | Abbexa | 100 ug | EUR 610.8 |
SURP And G-Patch Domain Containing 2 (SFRS14) Antibody |
|||
| abx027482-400ul | Abbexa | 400 ul | EUR 627.6 |
SURP And G-Patch Domain Containing 2 (SFRS14) Antibody |
|||
| abx027482-80l | Abbexa | 80 µl | EUR 343.2 |
G Patch Domain Containing Protein 2 (GPATCH2) Antibody |
|||
| abx233575-100ug | Abbexa | 100 ug | EUR 610.8 |
G Patch Domain Containing Protein 4 (GPATCH4) Antibody |
|||
| abx233576-100ug | Abbexa | 100 ug | EUR 661.2 |
G Patch Domain Containing Protein 4 (GPATCH4) Antibody |
|||
| abx030423-400ul | Abbexa | 400 ul | EUR 627.6 |
G Patch Domain Containing Protein 4 (GPATCH4) Antibody |
|||
| abx030423-80l | Abbexa | 80 µl | EUR 343.2 |
G Patch Domain-Containing Protein 8 (GPATCH8) Antibody |
|||
| 20-abx215677 | Abbexa |
|
|
GPAT1 Peptide |
|||
| 4613P | ProSci | 0.05 mg | EUR 197.7 |
|
Description: (CT) GPAT1 peptide |
|||
Gpatch4/ Rat Gpatch4 ELISA Kit |
|||
| ELI-27872r | Lifescience Market | 96 Tests | EUR 1063.2 |
GPATCH1 siRNA |
|||
| 20-abx918332 | Abbexa |
|
|
GPATCH1 siRNA |
|||
| 20-abx918333 | Abbexa |
|
|
GPATCH2 siRNA |
|||
| 20-abx918336 | Abbexa |
|
|
GPATCH2 siRNA |
|||
| 20-abx918337 | Abbexa |
|
|
GPATCH3 siRNA |
|||
| 20-abx918338 | Abbexa |
|
|
GPATCH3 siRNA |
|||
| 20-abx918339 | Abbexa |
|
|
GPATCH4 siRNA |
|||
| 20-abx918340 | Abbexa |
|
|
GPATCH4 siRNA |
|||
| 20-abx918341 | Abbexa |
|
|
GPATCH8 siRNA |
|||
| 20-abx918342 | Abbexa |
|
|
GPATCH8 siRNA |
|||
| 20-abx918343 | Abbexa |
|
|
GPATCH11 siRNA |
|||
| 20-abx918330 | Abbexa |
|
|
GPATCH11 siRNA |
|||
| 20-abx918331 | Abbexa |
|
|
GPATCH2L siRNA |
|||
| 20-abx918334 | Abbexa |
|
|
GPATCH2L siRNA |
|||
| 20-abx918335 | Abbexa |
|
|
GPATCH2 Rabbit pAb |
|||
| A17175-100ul | Abclonal | 100 ul | EUR 369.6 |
GPATCH2 Rabbit pAb |
|||
| A17175-200ul | Abclonal | 200 ul | EUR 550.8 |
GPATCH2 Rabbit pAb |
|||
| A17175-20ul | Abclonal | 20 ul | EUR 219.6 |
GPATCH2 Rabbit pAb |
|||
| A17175-50ul | Abclonal | 50 ul | EUR 267.6 |
GPATCH2 ELISA KIT|Human |
|||
| EF009939 | Lifescience Market | 96 Tests | EUR 826.8 |
GPATCH4 ELISA KIT|Human |
|||
| EF009940 | Lifescience Market | 96 Tests | EUR 826.8 |
Gpatc2 ORF Vector (Rat) (pORF) |
|||
| ORF067728 | ABM | 1.0 ug DNA | EUR 607.2 |
Gpatch1 ORF Vector (Rat) (pORF) |
|||
| ORF067729 | ABM | 1.0 ug DNA | EUR 607.2 |
Gpatch4 ORF Vector (Rat) (pORF) |
|||
| ORF067730 | ABM | 1.0 ug DNA | EUR 607.2 |
Rat GPATCH4 shRNA Plasmid |
|||
| 20-abx988741 | Abbexa |
|
|
GPATC2 ORF Vector (Human) (pORF) |
|||
| ORF004567 | ABM | 1.0 ug DNA | EUR 114 |
Gpatc2 3'UTR GFP Stable Cell Line |
|||
| TU255285 | ABM | 1.0 ml | Ask for price |
GPATCH4 cloning plasmid |
|||
| CSB-CL729203HU-10ug | Cusabio | 10ug | EUR 279.6 |
|
Description: A cloning plasmid for the GPATCH4 gene. |
|||
GPATCH2 cloning plasmid |
|||
| CSB-CL865155HU-10ug | Cusabio | 10ug | EUR 279.6 |
|
Description: A cloning plasmid for the GPATCH2 gene. |
|||
GPATCH4 ORF Vector (Human) (pORF) |
|||
| ORF004568 | ABM | 1.0 ug DNA | EUR 114 |
GPATCH1 ORF Vector (Human) (pORF) |
|||
| ORF020319 | ABM | 1.0 ug DNA | Ask for price |
GPATCH2 ORF Vector (Human) (pORF) |
|||
| ORF020320 | ABM | 1.0 ug DNA | Ask for price |
GPATCH3 ORF Vector (Human) (pORF) |
|||
| ORF020321 | ABM | 1.0 ug DNA | Ask for price |
GPATCH8 ORF Vector (Human) (pORF) |
|||
| ORF020322 | ABM | 1.0 ug DNA | EUR 790.8 |
Gpatch1 ORF Vector (Mouse) (pORF) |
|||
| ORF046415 | ABM | 1.0 ug DNA | EUR 607.2 |
Gpatch2 ORF Vector (Mouse) (pORF) |
|||
| ORF046416 | ABM | 1.0 ug DNA | EUR 607.2 |
Gpatch3 ORF Vector (Mouse) (pORF) |
|||
| ORF046417 | ABM | 1.0 ug DNA | EUR 607.2 |
Gpatch4 ORF Vector (Mouse) (pORF) |
|||
| ORF046418 | ABM | 1.0 ug DNA | EUR 607.2 |
Gpatch4 ORF Vector (Mouse) (pORF) |
|||
| ORF046419 | ABM | 1.0 ug DNA | EUR 607.2 |
Gpatch8 ORF Vector (Mouse) (pORF) |
|||
| ORF046420 | ABM | 1.0 ug DNA | EUR 1886.4 |
GPATCH1 3'UTR GFP Stable Cell Line |
|||
| TU059104 | ABM | 1.0 ml | EUR 1672.8 |
GPATCH2 3'UTR GFP Stable Cell Line |
|||
| TU059105 | ABM | 1.0 ml | EUR 2799.6 |
GPATCH3 3'UTR GFP Stable Cell Line |
|||
| TU059106 | ABM | 1.0 ml | EUR 1672.8 |
GPATCH4 3'UTR GFP Stable Cell Line |
|||
| TU059107 | ABM | 1.0 ml | EUR 1672.8 |
GPATCH8 3'UTR GFP Stable Cell Line |
|||
| TU059108 | ABM | 1.0 ml | EUR 1825.2 |
Gpatch1 3'UTR GFP Stable Cell Line |
|||
| TU255286 | ABM | 1.0 ml | Ask for price |
Gpatch3 3'UTR GFP Stable Cell Line |
|||
| TU255287 | ABM | 1.0 ml | Ask for price |
Gpatch4 3'UTR GFP Stable Cell Line |
|||
| TU255288 | ABM | 1.0 ml | Ask for price |
Gpatch1 3'UTR GFP Stable Cell Line |
|||
| TU158927 | ABM | 1.0 ml | Ask for price |
Gpatch2 3'UTR GFP Stable Cell Line |
|||
| TU158928 | ABM | 1.0 ml | Ask for price |
Gpatch4 3'UTR GFP Stable Cell Line |
|||
| TU158929 | ABM | 1.0 ml | Ask for price |
Gpatch8 3'UTR GFP Stable Cell Line |
|||
| TU158930 | ABM | 1.0 ml | Ask for price |
Mouse GPATCH8 shRNA Plasmid |
|||
| 20-abx982321 | Abbexa |
|
|
Mouse GPATCH3 shRNA Plasmid |
|||
| 20-abx982598 | Abbexa |
|
|
Mouse GPATCH4 shRNA Plasmid |
|||
| 20-abx975701 | Abbexa |
|
|
Mouse GPATCH1 shRNA Plasmid |
|||
| 20-abx976167 | Abbexa |
|
|
Mouse GPATCH2 shRNA Plasmid |
|||
| 20-abx976308 | Abbexa |
|
|
Human GPATCH8 shRNA Plasmid |
|||
| 20-abx958020 | Abbexa |
|
|
Human GPATCH1 shRNA Plasmid |
|||
| 20-abx960462 | Abbexa |
|
|
Human GPATCH2 shRNA Plasmid |
|||
| 20-abx960469 | Abbexa |
|
|
Human GPATCH3 shRNA Plasmid |
|||
| 20-abx961854 | Abbexa |
|
|
GPATCH8 Blocking Peptide |
|||
| DF9522-BP | Affbiotech | 1mg | EUR 234 |
Moreover, we confirmed that roots of rye crops took up compounds originating from neighbouring crops. Among the many compounds taken up by rye roots, wogonin was detected within the rye shoot, which indicated a root-to-shoot translocation of this compound.